Intelligence · Patents
Patents expiring in 2039
Annual patent cliff calendar for 2039 — US pharmaceutical patents by expiration date.
- Patents
- 1,782
Quick answer
1,782 indexed pharmaceutical patents have expiration dates in 2039. Browse by soonest expiry with links to assignee companies and related drugs.
-
US 10500284
Pharmaceutical formulation
granted -
US 10500277
Combination tumor treatment with drug-loaded, bispecific ligand-targeted minicells and interferon-gamma
granted -
US 10500264
Development of mutations useful for attenuating dengue viruses and chimeric dengue viruses
granted -
US 10500167
Droplet-embedded microfibers, and methods and devices for preparing and using same
granted -
US 10500261
Synthetic antigen constructs against campylobacter jejuni
granted -
US 10500194
Covalent small molecule DCN1 inhibitors and therapeutic methods using the same
granted -
US 10499682
Micronutrient formulation in electronic cigarettes
granted -
US 10500156
Multi-compartmental macrophage delivery
granted -
US 10500177
Glutarate compounds for treating ischemia-reperfusion injuries
granted -
US 10500175
Compositions and methods for the treatment of cancer
granted -
US 10500238
Use of gram negative species to treat atopic dermatitis
granted -
US 10500208
Emulsion formulations of aprepitant
granted -
US 10500216
Optimizing mifepristone absorption
granted -
EP 3576795
ORALES SCHILDDRÜSENTHERAPEUTIKUM
granted -
US 2019374520
TREATMENT OF MIGRAINE
granted -
US 2019374518
TREATMENT OF MIGRAINE
granted -
US 10507187
Regenerative tissue grafts and methods of making same
granted -
US 10508083
Substituted piperidine compound and use thereof
granted -
US 10508106
Bicyclic BET bromodomain inhibitors and uses thereof
granted -
US 10508103
Benzimidazole-linked indole compound acting as novel divalent IAP antagonist
granted -
US 10507225
Powder for regulating intestinal flora and protecting gastric mucosa, preparation method and use thereof
granted -
US 10507211
Treatment for hereditary neuropathy with liability to pressure palsies (HNPP)
granted -
US 10507284
Daily periodic target-zone modulation in the model predictive control problem for artificial pancreas for type I diabetes applications
granted -
US 10508129
Pharmaceutical targeting of a mammalian cyclic di-nucleotide signaling pathway
granted -
US 10507237
Attenuated African swine fever virus vaccine
granted -
US 10508122
Heterocyclic hydroxamic acids as protein deacetylase inhibitors and dual protein deacetylase-protein kinase inhibitors and methods of use thereof
granted -
US 10508136
Peptides and compositions for prevention of cell adhesion and methods of using same
granted -
US 10507239
V1/V2 fragments of a HIV-1 envelope glycoprotein
granted -
US 10508134
Peptide compositions and methods of use
granted -
US 10508140
Peptide having hair growth-promoting activity and/or melanin generation-promoting activity, and use thereof
granted -
US 10508307
Methods of diagnosing chronic obstructive pulmonary disease (COPD) using novel molecular biomarkers
granted -
CA 3102476
ASSOCIATIONS PHARMACEUTIQUES
granted -
US 10513521
Compositions and methods for inhibiting BMP
granted -
US 10513558
Anti-PD1 antibodies, activatable anti-PD1 antibodies, and methods of use thereof
granted -
US 10513543
Antigen chimera, antigen composition, vaccine, method of preparing the same and cassette thereof
granted -
US 10513532
Compound containing dexpanthenol
granted -
US 10512691
Systems and methods for targeted imaging and ablation of cardiac cells
granted -
US 10512669
Blockade of inflammatory proteases with cyclic peptides
granted -
US 10513712
Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription
granted -
US 10513703
Hepatitis B virus (HBV) iRNA compositions and methods of use thereof
granted -
US 10513587
Self-integrating hydrogels and methods for making the same
granted -
US 10513557
Anti-ASIC1 antibodies and uses thereof
granted -
US 10513542
Minicircle DNA vector vaccine platform for foot-and-mouth disease and methods thereof
granted -
US 10513549
Cleavage-activatable interferon-alpha proprotein
granted -
US 10513533
Tunicamycin related compounds with anti-bacterial activity
granted -
US 10513526
Solid state forms of spiro-oxindole compounds
granted -
US 10512687
Compositions and methods for enhanced innate immunity
granted -
US 10513494
Methods, compounds, and compositions for anesthesia
granted
Frequently asked questions
How many pharma patents expire in 2039?
1,782 published patents in our USPTO index have expiration dates falling in calendar year 2039.